Goldfarb Branham LLP is investigating Micrus Endovascular’s Board of Directors (NASDAQ: MEND) due to the recent merger they approved with Johnson & Johnson for a 5.5% premium. Micrus shareholders are encouraged to contact attorney Hamilton Lindley at 877-583-2855 or by email hlindley@goldfarbbranham.com for details about their rights.

“If the transaction closes, Micrus investors will be cashed out at $23.40 per share,” stated shareholder lawyer Hamilton Lindley. “Micrus may not have adequately shopped itself before entering into this transaction, and Johnson & Johnson may be underpaying for Micrus, thus unlawfully harming Micrus shareholders.”

If you own Micrus stock and you wish to discuss this matter with an experienced shareholder attorney, please contact Hamilton Lindley at 877-583-2855 or by email at hlindley@goldfarbbranham.com. Goldfarb Branham LLP lawyers have excellent experience representing shareholders in buyout cases nationwide. The firm provides nimble, creative and effective counsel at all stages of litigation.

Micrus Endovascular (MM) (NASDAQ:MEND)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025 Plus de graphiques de la Bourse Micrus Endovascular (MM)
Micrus Endovascular (MM) (NASDAQ:MEND)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025 Plus de graphiques de la Bourse Micrus Endovascular (MM)